Literature DB >> 33862513

Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.

Bo Wang1, Jin Liu1, Ira Tandon2, Suzhen Wu1, Peng Teng1, Jianhua Liao1, Weiping Tang3.   

Abstract

Proteolysis targeting chimeras (PROTACs) have gained tremendous interest in both the academic and pharmaceutical communities. This opens a new way to regulate the cellular protein homeostasis, especially for disease-related proteins. In this work, we designed and synthesized a series of MDM2 degraders based on ligands that were readily prepared by a four-component Ugi reaction. After extensive optimization based on anti-proliferation and MDM2 degradation, WB214 was identified as the most potent anti-proliferative agent in various leukemia cell lines. Surprisingly, our mechanistic investigations indicated that WB214 not only effectively induced the degradation of MDM2, but also led to the degradation of p53. Further studies revealed that WB214 degraded MDM2 as a molecular glue. WB214 and its related analogues did not bind to MDM2 in the p53 binding region and MDM2 was discovered as a novel neo-substrate of the E3 ligase cereblon. Finally, we found that WB214 could potently degrade GSPT1, which could rationalize the inhibition of cell growth. A selective degrader for GSPT1 over MDM2 was then developed through systematically varying different motifs.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  GSPT1; MDM2 degraders; Molecular glue; PROTAC

Mesh:

Substances:

Year:  2021        PMID: 33862513      PMCID: PMC8165035          DOI: 10.1016/j.ejmech.2021.113425

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   7.088


  43 in total

1.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

2.  Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Authors:  Daqing Sun; Zhihong Li; Yosup Rew; Michael Gribble; Michael D Bartberger; Hilary P Beck; Jude Canon; Ada Chen; Xiaoqi Chen; David Chow; Jeffrey Deignan; Jason Duquette; John Eksterowicz; Benjamin Fisher; Brian M Fox; Jiasheng Fu; Ana Z Gonzalez; Felix Gonzalez-Lopez De Turiso; Jonathan B Houze; Xin Huang; Min Jiang; Lixia Jin; Frank Kayser; Jiwen Jim Liu; Mei-Chu Lo; Alexander M Long; Brian Lucas; Lawrence R McGee; Joel McIntosh; Jeff Mihalic; Jonathan D Oliner; Tao Osgood; Matthew L Peterson; Philip Roveto; Anne Y Saiki; Paul Shaffer; Maria Toteva; Yingcai Wang; Yu Chung Wang; Sarah Wortman; Peter Yakowec; Xuelei Yan; Qiuping Ye; Dongyin Yu; Ming Yu; Xiaoning Zhao; Jing Zhou; Jiang Zhu; Steven H Olson; Julio C Medina
Journal:  J Med Chem       Date:  2014-02-05       Impact factor: 7.446

3.  Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Authors:  Jiuling Yang; Yangbing Li; Angelo Aguilar; Zhaomin Liu; Chao-Yie Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2019-10-21       Impact factor: 7.446

4.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

Authors:  Yukihiro Itoh; Minoru Ishikawa; Mikihiko Naito; Yuichi Hashimoto
Journal:  J Am Chem Soc       Date:  2010-04-28       Impact factor: 15.419

5.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

6.  Prospecting for molecular glues.

Authors:  Willem den Besten; J Russell Lipford
Journal:  Nat Chem Biol       Date:  2020-11       Impact factor: 15.040

7.  Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.

Authors:  Carl C Ward; Jordan I Kleinman; Scott M Brittain; Patrick S Lee; Clive Yik Sham Chung; Kenneth Kim; Yana Petri; Jason R Thomas; John A Tallarico; Jeffrey M McKenna; Markus Schirle; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

8.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

9.  Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.

Authors:  Nobumichi Ohoka; Genichiro Tsuji; Takuji Shoda; Takuma Fujisato; Masaaki Kurihara; Yosuke Demizu; Mikihiko Naito
Journal:  ACS Chem Biol       Date:  2019-10-16       Impact factor: 5.100

10.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

View more
  5 in total

1.  PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors:  Xin Han; Wenyi Wei; Yi Sun
Journal:  Acta Mater Med       Date:  2022-05-31

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.

Authors:  Haohao Zhu; Hui Gao; Yingying Ji; Qin Zhou; Zhiqiang Du; Lin Tian; Ying Jiang; Kun Yao; Zhenhe Zhou
Journal:  J Hematol Oncol       Date:  2022-07-13       Impact factor: 23.168

4.  Targeted Protein Degradation: An Important Tool for Drug Discovery for "Undruggable" Tumor Transcription Factors.

Authors:  Mengyuan Dai; Sridhar Radhakrishnan; Rui Li; Ruirong Tan; Kuo Yan; Gang Fan; Miao Liu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 5.  Drugging p53 in cancer: one protein, many targets.

Authors:  Ori Hassin; Moshe Oren
Journal:  Nat Rev Drug Discov       Date:  2022-10-10       Impact factor: 112.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.